ANI PHARMACEUTICALS, INC Net Cash Provided by (Used in) Continuing Operations
ANI PHARMACEUTICALS, INC (ANIP) reported Net Cash Provided by (Used in) Continuing Operations of -$3.69 million for the 12-month period ending 2013-12-31, per its 10-K filed 2014-02-28.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:NetCashProvidedByUsedInContinuingOperations · last filed 2014-02-28
- ANI PHARMACEUTICALS, INC net cash provided by (used in) continuing operations for the quarter ending 2013-12-31 was $808.87K, a 27.10% increase year-over-year.
- ANI PHARMACEUTICALS, INC net cash provided by (used in) continuing operations for the quarter ending 2013-09-30 was $0.00, a 100.00% decline year-over-year.
- ANI PHARMACEUTICALS, INC net cash provided by (used in) continuing operations for the quarter ending 2013-06-30 was $907.70K, a 88.19% decline year-over-year.
- ANI PHARMACEUTICALS, INC net cash provided by (used in) continuing operations for the quarter ending 2013-03-31 was -$5.41M.
- ANI PHARMACEUTICALS, INC net cash provided by (used in) continuing operations for fiscal 2013 was -$3.69M, a 598.51% decline from fiscal 2012.
- ANI PHARMACEUTICALS, INC net cash provided by (used in) continuing operations for fiscal 2012 was $740.00K, a 96.12% decline from fiscal 2011.
- ANI PHARMACEUTICALS, INC net cash provided by (used in) continuing operations for fiscal 2011 was $19.07M, a 129.85% increase from fiscal 2010.
- ANI PHARMACEUTICALS, INC net cash provided by (used in) continuing operations for fiscal 2010 was $8.30M.
| Period end | Net Cash Provided by (Used in) Continuing Operations 3 month | Net Cash Provided by (Used in) Continuing Operations 6 month | Net Cash Provided by (Used in) Continuing Operations 6 month as first filed | Net Cash Provided by (Used in) Continuing Operations 9 month | Net Cash Provided by (Used in) Continuing Operations 9 month as first filed | Net Cash Provided by (Used in) Continuing Operations 12 month | Net Cash Provided by (Used in) Continuing Operations 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2013-12-31 | $808.87K derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-28 | $808.87K derived: sum of 2 quarters · filed 2014-02-28 | $1.72M derived: sum of 3 quarters · filed 2014-02-28 | -$3.69M 10-K · filed 2014-02-28 | |||
| 2013-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-07 | $907.70K derived: sum of 2 quarters · filed 2013-11-07 | -$4.50M 10-Q · filed 2013-11-07 | -$3.86M derived: sum of 4 quarters · filed 2014-02-28 | |||
| 2013-06-30 | $907.70K derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-09 | -$4.50M 10-Q · filed 2013-08-09 | -$3.86M derived: sum of 3 quarters · filed 2014-02-28 | -$3.69M derived: sum of 4 quarters · filed 2014-02-28 | |||
| 2013-03-31 | -$5.41M 10-Q · filed 2013-05-10 | -$4.77M derived: sum of 2 quarters · filed 2014-02-28 | -$4.60M derived: sum of 3 quarters · filed 2014-02-28 | $3.09M derived: sum of 4 quarters · filed 2014-02-28 | |||
| 2012-12-31 | $636.39K derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-28 | $807.18K derived: sum of 2 quarters · filed 2014-02-28 | $8.49M derived: sum of 3 quarters · filed 2014-02-28 | $740.00K 10-K · filed 2014-02-28 | -$22.43M 10-K · filed 2013-02-28 | ||
| 2012-09-30 | $170.80K derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-07 | $7.86M derived: sum of 2 quarters · filed 2013-11-07 | $103.61K 10-Q · filed 2013-11-07 | -$19.18M 10-Q · filed 2012-11-08 | -$12.27M derived: sum of 4 quarters · filed 2013-11-07 | ||
| 2012-06-30 | $7.68M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-09 | -$67.18K 10-Q · filed 2013-08-09 | -$14.81M 10-Q · filed 2012-08-01 | -$12.44M derived: sum of 3 quarters · filed 2013-08-09 | $20.03M derived: sum of 4 quarters · filed 2013-08-09 | ||
| 2012-03-31 | -$7.75M 10-Q · filed 2013-05-10 | -$20.13M derived: sum of 2 quarters · filed 2013-05-10 | $12.35M derived: sum of 3 quarters · filed 2013-05-10 | -$1.88M derived: sum of 4 quarters · filed 2013-05-10 | |||
| 2011-12-31 | -$12.37M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-28 | $20.10M derived: sum of 2 quarters · filed 2013-02-28 | $5.88M derived: sum of 3 quarters · filed 2013-02-28 | $19.07M 10-K · filed 2013-02-28 | |||
| 2011-09-30 | $32.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-08 | $18.25M derived: sum of 2 quarters · filed 2012-11-08 | $31.44M 10-Q · filed 2012-11-08 | ||||
| 2011-06-30 | -$14.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-01 | -$1.03M 10-Q · filed 2012-08-01 | |||||
| 2011-03-31 | $13.19M 10-Q · filed 2012-05-08 | ||||||
| 2010-12-31 | $8.30M 10-K · filed 2013-02-28 | ||||||
| 2009-12-31 | $18.10M 8-K · filed 2013-01-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |